Development of new scaffolds as reversible tissue transglutaminase inhibitors, with improved potency or resistance to glutathione addition.
Sign Up to like & getrecommendations! Published in 2017 at "MedChemComm"
DOI: 10.1039/c6md00565a
Abstract: Previous studies within our group have yielded a class of cinnamoyl-based competitive reversible inhibitors for tissue transglutaminase (TG2), with Ki values as low as 1.0 μM (compound CP4d). However, due to the electrophilic nature of… read more here.
Keywords: development new; potency; transglutaminase; new scaffolds ... See more keywords
Harnessing Protein-Ligand Interaction Fingerprints to Predict New Scaffolds of RIPK1 Inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Molecules"
DOI: 10.3390/molecules27154718
Abstract: Necroptosis has emerged as an exciting target in oncological, inflammatory, neurodegenerative, and autoimmune diseases, in addition to acute ischemic injuries. It is known to play a role in innate immune response, as well as in… read more here.
Keywords: machine learning; ripk1 inhibitors; harnessing protein; new scaffolds ... See more keywords